Effects of Exenatide on Motor Function and the Brain

Parkinson's Disease Clinical Trial

Official title:

Effects of Exenatide on Motor Function and the Brain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03456687
• Other study ID #: IRB201703187 - N
• Secondary ID: R01NS052318OCR17
• Status: Completed
• Phase: Phase 1
• Start date: June 5, 2018
• Est. completion date: August 25, 2021

Study information

• Verified date: September 2022
• Source: University of Florida
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to investigate how the brain and motor behavior changes Parkinson's Disease (PD) over time in response to Exenatide. In previous clinical trials, PD patients have experienced symptomatic improvement on Exenatide and literature suggests it may help slow the progression of Parkinson's. Both will be evaluated in this study.

Description:

Participants will receive baseline testing to confirm a diagnosis of Parkinson's Disease and to determine eligibility in the research study. All of the participants in this study will receive the study drug (Exenatide). The study drug will be provided at the end of the first visit, and participants will be administered the drug once per week for the duration of the study (1 year).

During the research study the following test may occur: (1) questionnaires about quality of life and depression; (2) tests to measure strength and motor function; (3) tests to measure cognition; (4) orientation session to learn a precision gripping task; (5) functional MRI scan of the brain; (6) structural MRI scan of the brain.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: August 25, 2021
• Est. primary completion date: October 16, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 77 Years

Eligibility

Inclusion Criteria:

• patients clinically diagnosed with Parkinson's disease (PD) through use of the UK PD brain bank diagnostic criteria

• early stage PD patients within 5 years of diagnosis who have never taken Exenatide for any reason

• PD patients with a Hoehn and Yahr stage less than or equal to 2 when on medication

• patients able and willing to sign informed consent.

Exclusion Criteria:

• individuals who have any type of implanted electrical device (such as a cardiac pacemaker or a neurostimulator)

• individuals with a certain type of metallic clip in the body (i.e., an aneurysm clip in the brain)

• claustrophobia

• women who are or might be pregnant and nursing mothers. Pregnancy tests will be carried out for each female subject prior to the MRI scan.

• psychiatric disorders or dementia

• other neurologic and orthopedic problems that impair hand movements and walking

• individuals actively participating in another trial of a device, drug or surgical treatment for Parkinson's disease

• individuals who have a history metalworking involving cutting processes such as grinding, filing, shaving, and threading, will need radiological clearance to participate in this study. Specifically, individuals who report a history of metalworking will be referred to Radiology at Shands University of Florida(UF) for an orbitofrontal x-ray.

• individuals who have sustained an eye injury involving metal will also be referred to Radiology at Shands UF for an orbitofrontal x-ray.

• prior stroke or brain tumor

• cognitive impairment as assessed by a Montreal Cognitive Assessment score < 23

• individuals unwilling to comply with the study procedures

• history of gallstones, digestion problems (such as gastroparesis), severe gastrointestinal disease, history of pancreatitis, a thyroid tumor or cancer, pancreas tumor, or kidney problems

• severely impaired renal function with creatinine clearance less than 30 ml/min

• hyperlipidemia defined as more than two times the upper limit of normal

• body mass index less than 18.5

• previous exposure to Exenatide

• diabetes

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Drug:
• Exenatide
Exenatide will be administered through a subcutaneous injection once per week for the duration of the study (1 year).

Locations

Country	Name	City	State
United States	Laboratory for Rehabilitation Neuroscience	Gainesville	Florida

Sponsors (2)

Lead Sponsor	Collaborator
University of Florida	National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in free-water accumulation in the substantia nigra	12-month study in PD to watch the effect of Exenatide on the progressive increase of free-water accumulation in the substantia nigra.	Baseline and one-year
Primary	Change in blood oxygen level-dependent(BOLD) signal in the posterior putamen.	12-month study in PD to watch the effect of Exenatide on BOLD signal in the posterior putamen.	Baseline and one-year
Primary	Change in blood oxygen level-dependent(BOLD) signal in M1.	12-month study in PD to watch the effect of Exenatide on BOLD signal in M1.	Baseline and one-year
Primary	Change in blood oxygen level-dependent(BOLD) signal in the supplementary motor area(SMA).	12-month study in PD to watch the effect of Exenatide on BOLD signal in the SMA.	Baseline and one-year